|
|
|
|
Archives
|
Entry
|
Author
|
Date
|
Location
|
|
Seattle Genetics’ New ‘Empowered Antibody’ Looks Clean in FDA Staff Documents
|
Luke Timmerman |
07/12/11 |
Seattle
|
|
Seattle Genetics’ FDA Panel Preview: What You Need to Know This Week
|
Luke Timmerman |
07/12/11 |
Seattle
|
|
SeaGen Preserves Science Culture, Dendreon Sways Medicare, NanoString’s Financing, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
07/07/11 |
Seattle
|
|
Seattle Genetics, On the Verge of Going Commercial, Seeks to Keep Its Scientific Soul
|
Luke Timmerman |
07/05/11 |
Seattle
|
|
Allozyne’s Backdoor IPO, Sound Pharma Fights iPod Deafness, Mirina Vs. Marina Ends, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
06/23/11 |
Seattle
|
|
Cyterix Develops New Twist on an Old Idea, With ‘Smart Bomb’ Cancer Drugs
|
Luke Timmerman |
06/22/11 |
San Francisco
|
|
SeaGen Promotes Dobmeier
|
Luke Timmerman |
06/17/11 |
Seattle
|
|
ASCO Wrap-Up, Pathway Medical Grinds It Out, Gates Foundation’s New Digs, & More in Seattle-Area Life Sciences News
|
Luke Timmerman |
06/09/11 |
Seattle
|
|
ASCO Wrap-Up: The Skinny on Cancer News From All Corners of the U.S.
|
Luke Timmerman |
06/07/11 |
National
|
|
Resolve Maps Out New Biotech Model, SeaGen Expands, Schadt Heads East, & More in Seattle-Area Life Sciences News
|
Luke Timmerman |
05/19/11 |
Seattle
|
|
SeaGen Adds $7.7M Lease
|
Luke Timmerman |
05/13/11 |
Seattle
|
|
Geospiza Sells to PerkinElmer, PATH Vaccine Nabs $100M, Halosource Gets China Approval, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
05/12/11 |
Seattle
|
|
Why Are Drugs Getting Such Weird Brand Names?
|
Luke Timmerman |
05/09/11 |
National
|
|
SeaGen Ends March With $456M Cash
|
Luke Timmerman |
05/05/11 |
Seattle
|
|
Kleiner Perkins’ Bet on a Concrete Stomach, The Gates Foundation’s Out-of-the-Box Ideas, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
05/05/11 |
Seattle
|
|
SeaGen FDA Deadline Set for Aug. 30
|
Luke Timmerman |
05/02/11 |
Seattle
|
|
Life Science Discovery Fund Faces Cuts, Boeing’s Biofuel Push, SeaGen’s Latest Deal, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
04/21/11 |
Seattle
|
|
Genmab Expands SeaGen Alliance
|
Luke Timmerman |
04/19/11 |
Seattle
|
|
SeaGen Strikes Abbott Deal, Omeros Passes Study, Alnylam Fires Back at Tekmira, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
03/24/11 |
Seattle
|
|
SeaGen Inks Abbott Deal
|
Luke Timmerman |
03/22/11 |
Seattle
|
|
Think Obamacare Will Suffocate New Drug Development With Price Controls? Think Again
|
Luke Timmerman |
03/21/11 |
National
|
|
SeaGen Expands Millennium Deal
|
Luke Timmerman |
03/15/11 |
Seattle
|
|
Where Are Tomorrow’s Blockbuster Biotech Drugs Coming From? You Might be Surprised
|
Luke Timmerman |
03/14/11 |
National
|
|
Dendreon Moves Across Town, SeaGen Files FDA App, Alder Takes Road Less Traveled, & More Seattle Life Sciences News
|
Luke Timmerman |
03/03/11 |
Seattle
|
|
SeaGen Turns in FDA Application
|
Luke Timmerman |
02/28/11 |
Seattle
|
|
Dendreon Adds $80M, Amgen Advances ‘Son of Dmab,’ Mobisante Wins FDA OK, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
02/10/11 |
Seattle
|
|
SeaGen Expects $280M Cash at Year End
|
Luke Timmerman |
02/08/11 |
Seattle
|
|
SeaGen Tacks on $23M
|
Luke Timmerman |
02/03/11 |
Seattle
|
|
Seattle Genetics Reloads, Uptake Ups and Leaves, PhysioSonics Raises Cash, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
02/03/11 |
Seattle
|
|
Seattle Genetics Reloads Cash Reserves With $155M, On Cusp of Selling First Drug
|
Luke Timmerman |
02/02/11 |
Seattle
|
|
Page 2 of
7 |
« previous page · next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.